Form 4: Richard van den Broek Acquires 30,000 Stock Options in Corvus Pharmaceuticals

Director Richard van den Broek acquired 30,000 stock options in Corvus Pharmaceuticals on April 8, 2025, according to a Form 4 filing.

Summary

• Richard van den Broek, a director of Corvus Pharmaceuticals, acquired 30,000 stock options on April 8, 2025.
• The exercise price of these options is $2.82.
• The options vest in three equal annual installments starting April 8, 2025, contingent upon continued service with Corvus Pharmaceuticals.
• The options expire on April 8, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options by a director suggests confidence in the company's future, but it's a routine transaction.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule of the options is tied to the director's continued service with the company, suggesting a commitment to Corvus Pharmaceuticals' future.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with those of shareholders.

Stakeholder Impact

• The acquisition of stock options by a director can positively influence shareholder sentiment.

Key Dates

Keywords

Corvus Pharmaceuticals, stock options, Form 4, director, Richard van den Broek, acquisition, CRVS